The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
His Pan-Slavic views were unleashed in this book, where he stated that the land of Slovaks should be annexed by the Tsar's empire and that eventually, the population could be not only Russified, but also converted into the rite of Orthodoxy, religion originally spread by Cyril and Methodius during the times of Great Moravia, which served as an opposition to the Catholic missionaries from the Franks. After the Hungarian invasion of Pannonia, Hungarians converted into Catholicism, which effectively influenced the Slavs living in Pannonia and in the land south of the Lechs. However, the Russian Empire often claimed Pan-Slavism as a justification for its aggressive moves in the Balkan Peninsula of Europe against the Ottoman Empire, which conquered and held the land of Slavs for centuries. This eventually led to the Balkan campaign of the Russian Empire, which resulted in the entire Balkan being liberated from the Ottoman Empire, with the help and the initiative of the Russian Empire. Pan-Slavism has some supporters among Czech and Slovak politicians, especially among the nationalistic and far-right ones, such as People's Party – Our Slovakia. The creation of an independent Czechoslovakia made the old ideals of Pan-Slavism anachronistic. Relations with other Slavic states varied, sometimes being so tense it escalated into an armed conflict, such as with the Second Polish Republic where border clashes over Silesia resulted in a short hostile conflict, the Polish–Czechoslovak War. Even tensions between Czechs and Slovaks had appeared before and during World War II.
The Drug Enforcement Administration (DEA) states, as an analogue of methcathinone, possession of mephedrone can be controlled by the Federal Analog Act, but according to the Los Angeles Times, this only applies if it is sold for human consumption. Several cities and states, such as New York state, have passed legislation to specifically list mephedrone as illegal, but in most areas it remained legal, so long as it is not sold for human consumption, so retailers described it as 'bath salts'. In September 2011, The DEA began using its emergency scheduling authority to temporarily control mephedrone. Except as authorised by law, this action made possessing and selling mephedrone or the products that contain it illegal in the US for at least one year while the DEA and the United States Department of Health and Human Services conduct further study. Control of these compounds became permanent on 9 July 2012, via passage of the Synthetic Drug Abuse Prevention Act of 2012.
=== Oxides and oxygen-containing salts === Protactinium oxides are known for the metal oxidation states +2, +4, and +5. The most stable is the white pentoxide Pa2O5, which can be produced by igniting protactinium(V) hydroxide in air at a temperature of 500 °C. Its crystal structure is cubic, and the chemical composition is often non-stoichiometric, described as PaO2.25. Another phase of this oxide with orthorhombic symmetry has also been reported. The black dioxide PaO2 is obtained from the pentoxide by reducing it at 1550 °C with hydrogen. It is not readily soluble in either dilute or concentrated nitric, hydrochloric, or sulfuric acid, but easily dissolves in hydrofluoric acid. The dioxide can be converted back to pentoxide by heating in oxygen-containing atmosphere to 1100 °C. The monoxide PaO has only been observed as a thin coating on protactinium metal, but not in an isolated bulk form. Protactinium forms mixed binary oxides with various metals. With alkali metals A, the crystals have a chemical formula APaO3 and perovskite structure; A3PaO4 and distorted rock-salt structure; or A7PaO6, where oxygen atoms form a hexagonal close-packed lattice. In all of these materials, the protactinium ions are octahedrally coordinated. The pentoxide Pa2O5 combines with rare-earth metal oxides R2O3 to form various nonstoichiometric mixed-oxides, also of perovskite structure. Protactinium oxides are basic; they easily convert to hydroxides and can form various salts, such as sulfates, phosphates, nitrates, etc.
Sources: en.wikipedia.org
=== TIME framework and Triangle of Wound Assessment (TWA) === To assist clinicians in standardizing the wound assessment and preparation of wound bed for treatment, the TIME framework was developed in 2002 by a group of wound care experts. The TIME acronym stands for Tissue, Infection/Inflammation, Moisture, and Edge – components that, per the TIME recommendation, should be thoroughly assessed to optimize the treatment. Depending on the clinical findings for each component, TIME recommends certain clinical actions aimed at correcting the issues and facilitating healing. A recent global anthropological study has prompted clinicians to review the TIME framework and resulted in a 2016 development of a comprehensive tool for wound assessment – the Triangle of Wound Assessment (TWA). Based on the study's findings, TWA identifies three zones (wound bed, wound edge, and periwound skin) that must be included in wound assessment to arrive at clinical decisions that will help heal the wound in the most efficient way. TIME framework components are integrated into the assessment of each zone. The introduction of periwound skin as a component of wound assessment identifies a significant departure from traditional methods; it emphasizes the importance of addressing periwound skin during treatment in the same measure as wound bed and wound edge. Wound assessment is a holistic process that considers the patient's current state of health, the factors that may impede wound healing, and the cause, duration and state of the wound. As such, this process is applicable to any wound.
== History == The concept of validation was first proposed by two Food and Drug Administration (FDA) officials, Ted Byers and Bud Loftus, in 1979 in USA, to improve the quality of pharmaceuticals. It was proposed in direct response to several problems in the sterility of large volume parenteral market. The first validation activities were focused on the processes involved in making these products, but quickly spread to associated processes including environmental control, media fill, equipment sanitization and purified water production. The concept of validation was first developed for equipment and processes and derived from the engineering practices used in delivery of large pieces of equipment that would be manufactured, tested, delivered and accepted according to a contract The use of validation spread to other areas of industry after several large-scale problems highlighted the potential risks in the design of products. The most notable is the Therac-25 incident. Here, the software for a large radiotherapy device was poorly designed and tested. In use, several interconnected problems led to several devices giving doses of radiation several thousands of times higher than intended, which resulted in the death of three patients and several more being permanently injured. In 2005 an individual wrote a standard by which the transportation process could be validated for cold chain products.
Freeman was cast at the suggestion of producer Liz Glotzer, despite the novella's character of a white Irishman. Filming proved to be challenging, mainly because of Darabont's need for multiple takes. Freeman said, "The answer [I'd give him] was no ... having to do something again and again for no discernible reason tends to be a bit debilitating to the energy." Nevertheless, his performance was described as "quietly impressive" and "moving" by The New York Times. At the 67th Academy Awards the film received Academy Award nominations for Best Picture and a nomination for Freeman for Best Actor losing to Tom Hanks in Forrest Gump (1994). Since its release, The Shawshank Redemption has remained popular among audiences. In 1994, Freeman served as a member of the jury at the 44th Berlin International Film Festival. Outbreak (1995), a medical thriller directed by Wolfgang Petersen, was Freeman's next film. He played General Billy Ford, a doctor dealing with an outbreak of a fictional virus in a small town. The film stars Dustin Hoffman, Rene Russo, and Donald Sutherland. Outbreak was a box-office success, grossing $189.8 million worldwide, but gained a mixed critics' response. Mick LaSelle of the San Francisco Chronicle credited Freeman for his performance which may have been unappreciated by viewers. In 1995, Freeman starred with Brad Pitt in David Fincher's crime thriller Seven, the story of two detectives who attempt to identify a serial killer who bases his murders on the Christian seven deadly sins.
== Training == In the beginning stages of working as a diener, there are training requirements. Formal training requirements for a diener includes manual handling, infection control, and safety procedures. The training has two parts: Taught Units and Workplace Competency. The first portion, Taught Units, consists of five sections.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.